Knight Therapeutics Q3 Revenue Beats on Product Growth and Currency Tailwind
Knight Therapeutics reported Q3 revenue above expectations, citing product growth and a currency tailwind.
Related stories
Lincoln International Reports Q3 2026 Financial Results
Lincoln International reported third-quarter and year-to-date revenues of $293.7 million and $677.1 million, respectively.
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC
Tripadvisor CEO Matt Goldberg to Depart in Leadership Transition
Tripadvisor said its board and CEO Matt Goldberg agreed he will leave as president and CEO and as a board member.
M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC
Korro Bio Reports Third-Quarter Loss per Share
M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC
REGENXBIO Reports Third-Quarter 2026 Results
REGENXBIO reported third-quarter 2026 financial results and operational highlights. Its RGX-202 BLA submission for Duchenne muscular dystrophy is on track for Q1 2027, with potenti
M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC
Lightspeed Commerce Expects Q3 Revenue of $310M-$320M
M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC
Unity Expects Q4 Revenue of $683M–$691M
M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC